Alfredo Quijano-Rubio

Alfredo Quijano-Rubio

Auto-generated profile, based on publicly available information

Alfredo Quijano-Rubio

Institute for Protein Design, University of Washington, Seattle, WA, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2019 in Nature
Verified
Journal Article
Closed access
PDF file
DSDaniel-Adriano Silva
Daniel-Adriano Silva
SYShawn Yu
Shawn Yu
UUUmut Y. Ulge
Umut Y. Ulge
JSJamie B. Spangler
Jamie B. Spangler
KJKevin M. Jude
Kevin M. Jude
DBDavid Baker
David Baker

27 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
AQAlfredo Quijano-Rubio
Alfredo Quijano-Rubio
HYHsien Wei Yeh
Hsien Wei Yeh
JPJooyoung Park
Jooyoung Park
HLHansol Lee
Hansol Lee
RLRobert A. Langan
Robert A. Langan
DBDavid Baker
David Baker

25 September 2020 in Science
Verified
Journal Article
Closed access
MLMarc J. Lajoie
Marc J. Lajoie
SBScott E. Boyken
Scott E. Boyken
ASAlexander I. Salter
Alexander I. Salter
JBJilliane Bruffey
Jilliane Bruffey
ARAnusha Rajan
Anusha Rajan
DBDavid Baker
David Baker
Logic at the cell surface: A major challenge in medical interventions is to target only diseased cells. Although there are biomarkers characteristic of certain cancers, for example, it is unlikely that a single marker can specify a particular cell type. Lajoie et al. addressed this problem by designing protein switches called Co-LOCKR that bind to antigens on the cell surface and activate through a conformational change only when there is a precise combination of antigens. They designed switches that can perform AND, OR, and NOT logic. On the path toward applying this technology, they used Co-LOCKR to direct chimeric antigen receptor T cells to tumor cells expressing specific antigens. Science , this issue p. 1637

17 May 2019 in Science
Verified
Journal Article
Closed access
PDF file
SBScott E. Boyken
Scott E. Boyken
MBMark Benhaim
Mark Benhaim
FBFlorian Busch
Florian Busch
MJMengxuan Jia
Mengxuan Jia
MBMatthew J. Bick
Matthew J. Bick
DBDavid Baker
David Baker
Designed to respond: Protein design has achieved success in finding sequences that fold to very stable target structures. Protein function, however, often requires conformational dynamics. Boyken et al. describe designed proteins that undergo conformational transitions in response to pH. They designed helical oligomers in which histidines are positioned in hydrogen-bond networks at the interfaces, with complimentary hydrophobic packing around the networks. Lowering the pH protonated the histidine, disrupting the oligomers. After endocytosis into low-pH compartments in cells, the designed proteins disrupted endosomal membranes. Science , this issue p. 658

3 January 2017 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MVMarta Vazquez-Vilar
Marta Vazquez-Vilar
AQAlfredo Quijano-Rubio
Alfredo Quijano-Rubio
AFAsun Fernandez-Del-Carmen
Asun Fernandez-Del-Carmen
ASAlejandro Sarrion-Perdigones
Alejandro Sarrion-Perdigones
RORocio Ochoa-Fernandez
Rocio Ochoa-Fernandez
DODiego Orzaez
Diego Orzaez
Modular DNA assembly simplifies multigene engineering in Plant Synthetic Biology. Furthermore, the recent adoption of a common syntax to facilitate the exchange of plant DNA parts (phytobricks) is a promising strategy to speed up genetic engineering. Following this lead, here, we present a platform for plant biodesign that incorporates functional descriptions of phytobricks obtained under pre-defined experimental conditions, and systematically registers the resulting information as metadata for documentation. To facilitate the handling of functional descriptions, we developed a new version (v3.0) of the GoldenBraid (GB) webtool that integrates the experimental data and displays it in the form of datasheets. We report the use of the Luciferase/Renilla (Luc/Ren) transient agroinfiltration assay in Nicotiana benthamiana as a standard to estimate relative transcriptional activities conferred by regulatory phytobricks, and show the consistency and reproducibility of this method in the characterization of a synthetic phytobrick based on the CaMV35S promoter. Furthermore, we illustrate the potential for combinatorial optimization and incremental innovation of the GB3.0 platform in two separate examples, (i) the development of a collection of orthogonal transcriptional regulators based on phiC31 integrase and (ii) the design of a small genetic circuit that connects a glucocorticoid switch to a MYB/bHLH transcriptional activation module.

31 October 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
AQAlfredo Quijano-Rubio
Alfredo Quijano-Rubio
ABAladdin M. Bhuiyan
Aladdin M. Bhuiyan
HYHuilin Yang
Huilin Yang
ILIsabel Leung
Isabel Leung
EBElisa Bello
Elisa Bello
DBDavid Baker
David Baker
The therapeutic potential of recombinant cytokines has been limited by the severe side effects of systemic administration. We describe a strategy to reduce the dose-limiting toxicities of monomeric cytokines by designing two components that require colocalization for activity and that can be independently targeted to restrict activity to cells expressing two surface markers. We demonstrate the approach with a previously designed mimetic of cytokines interleukin-2 and interleukin-15—Neoleukin-2/15 (Neo-2/15)—both for trans-activating immune cells surrounding targeted tumor cells and for cis-activating directly targeted immune cells. In trans-activation mode, tumor antigen targeting of the two components enhanced antitumor activity and attenuated toxicity compared with systemic treatment in syngeneic mouse melanoma models. In cis-activation mode, immune cell targeting of the two components selectively expanded CD8+ T cells in a syngeneic mouse melanoma model and promoted chimeric antigen receptor T cell activation in a lymphoma xenograft model, enhancing antitumor efficacy in both cases.